Krzysztof Narkiewicz  ESH大会主席、格丹斯克医科大学教授

    <International Circulation>:Can you give us an introduction to the reasons for the expansion of this year’s ESH meeting and the change in name， and what are some of the new features and topics we will see?

  《国际循环》：您能介绍一下今年ESH会议扩大及改名的原因吗，我们将看到哪些新亮点和议题？

    Prof. Narkiewicz:  Basically we know that the risk to hypertensive patients is determined by the presence of target organ damage and our guidelines stress the need for the evaluation of the target organ damage. Therefore we are not only interested in the reduction of blood pressure but the prevention of cardiovascular events and development of target organ damage. We are paying more and more attention to precise evaluation of target organ damage and at the end of the day， cardiovascular protection is the final goal of anti-hypertensive treatment. We have expanded our interests to the metabolic syndrome， to diabetes， to stroke， to congestive heart failure， to arrhythmias (because many arrhythmias are associated with hypertension) and there is quite significant development in terms of new drugs and in other fields， and new techniques for us to assess the cardiovascular damage done by high blood pressure. So this is the reason we decided to change the name. In the future， we do not wish to be confused with the European Society of Cardiology activity because they have the EuroPRevent meeting， and we will try to make it very clear that this is cardiovascular protection rather than just prevention. From next year it will be the European Meeting on Hypertension and Cardiovascular Protection. We stress the role of the assessment of large artery function so therefore we have many training workshops related to assessment of organ damage. We stress the role of pulse wave velocity on high blood pressure. There are many new companies coming onto the market with developments in terms of the assessment of artery function. We stress the role of the impairment of left ventricular function and diastolic dysfunction and advocate the use of echocardiography. Furthermore， we are very interested in the role of sleep apnea. Most of our patients with resistant hypertension should be screened for sleep apnea which requires techniques such as polysomnography and other measures of sleep.

    Narkiewicz教授：我们基本清楚高血压患者的风险取决于靶器官损害，我们的指南也强调评估靶器官损害的必要性。因此，我们不仅关注降压，也关注预防心血管事件和靶器官损害的进展。我们付诸越来越多的精力来精确评估靶器官损害，心血管保护是降压治疗的最终目标。我们的兴趣扩展至代谢综合症、糖尿病、卒中、充血性心力衰竭、心律失常（因为许多心律失常与高血压有关），在新药研发和其它领域有了长足的进展，新技术帮助我们评估高血压所致心血管损害。所以这是我们决定改名的原因。以后我们希望不要与欧洲心脏病学学会的活动混淆，因为他们有欧洲预防会议，我们将努力澄清这是心血管保护而不仅仅是预防。明年它将是欧洲高血压和心血管保护会议。我们强调评估大动脉功能的作用，因此，我们有很多与评估器官损害有关的研讨会。我们强调脉搏波传导速度对高血压的作用。有很多新的公司带着评估动脉功能的新成果走向市场。我们强调左室功能损害和舒张功能不全的作用，提倡应用超声心动图。此外，我们对睡眠呼吸暂停造成的影响很感兴趣。患难治性高血压的大多数患者应该筛查睡眠呼吸暂停，后者需要多导睡眠图等技术和其它监测睡眠的方法。